# A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

> **NCT06294548** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Valemetostat
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06294548
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-29
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-08-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06294548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06294548, "A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06294548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*